The
global Netupitant - Palonosetron FDC sales are expected to reach USD
515.0 million by 2018. The global Chemotherapy-induced nausea and
vomiting (CINV) market is estimated to reach USD 1.7 billion by 2015
at a growth rate of 7.1%, whereas country such as South Africa is
estimated to constitute 9% of the CINV market by 2015, due to
prevalent cancer related conditions and subsequent increase in CINV
patient pool. Asian region is expected to witness largest patient
share for CINV contributing majorly to the total CINV patient pool.
Hence, Asian market is expected to have huge growth potential for
Netupitant - Palonosetron FDC.
Browse
the full report at
http://www.transparencymarketresearch.com/netupitant-palonosetron-fdc-market.html
Chemotherapy
is one of the treatment options utilized by oncologists in treating
different types of cancers. Nausea and vomiting are the most common
side-effects experienced by cancer patients when administered with
chemotherapy. Netupitant-palonosetron, which is currently in Phase
III trials helps in preventing CINV. The blockage of P/NK1 receptors
by Netupitant in the central nervous system inhibits the binding of
endogenous tachykinin neuropeptide substance and this result in
preventing the chemotherapy-induced nausea and vomiting. Moreover,
Palonosetron helps in the blockage of serotonin at
5-hydroxytryptamine type 3 (5-HT3) receptors and it also helps in the
chemotherapy-induced nausea and vomiting.
Netupitant-Palonosetron
FDC is estimated to answer significant unmet needs of the CINV market
post its launch that is expected to be commercialized in 2014, as it
would overcome the problems associated with current treatment with
5-HT3 receptor antagonists. Similar to Emend, Netupitant-Palonosetron
FDC would gain considerable patient pool after its estimated launch
in 2014, and subsequently match the patient share of Aloxi by 2018.
Netupitant-Palonosetron FDC sales are expected to reach an estimated
USD 515.0 million USD by 2018. FDC combination of 5-HT3 receptor
antagonist and neurokinin-1 (NK1) receptor antagonist have shown
better efficacy results in Phase II clinical trials for CINV patients
and would thus lead to high uptake due to shifting physician and
patient preference pattern towards better treatment for CINV.
The
lack of approval to any other antagonist for the prevention of
delayed-onset CINV in patients getting highly emetogenic
chemotherapy, Palonosetron is expected to witness higher growth. It
is expected to grow at a higher rate during the forecasted period in
both developed and developing regions such as South Africa and Asia
among others.
Request
for customization of this report
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=729
CINV
can cause cancer patients to withdraw from therapy due to increased
medical costs, often leading to higher mortality and higher medical
spending. So, patients and providers would realize the benefits of
finding alternative CINV therapies, such as Netupitant-Palonosetron
FDC.
Browse
all Press Releases:
http://www.transparencymarketresearch.com/press-releases.htm
New
entrants to this market have historically benefited from rapid
uptake, driven both by clinical advantages and by favorable
reimbursement dynamics, from which Netupitant-Palonosetron FDC is
poised to benefit upon approval.
Browse
all Article :
http://www.transparencymarketresearch.com/articles.htm
There
is certain advantage of the Netupitant - Palonosetron as it would be
the only FDC approved for treating chemotherapy induced nausea and
vomiting that is likely to drive this market in the near future.
Moreover, it is effective in the body for longer period of time and
will help in achieving better patient compliance. However, lack in
the number of clinical trials is likely to slower the growth of this
market but the rising cancer population is likely to further create
an opportunity in this market.
Browse
all Medical
Devices Market Research Reports
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are
privileged with highly experienced team of Analysts, Researchers, and
Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Sheela
AK
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
No comments:
Post a Comment